Home

Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros

Bayer supports rebuilding of the Ukrainian healthcare system with a donation of 1.3 million euros to the UNITED24 fundraising platform. UNITED24 was launched in May 2022 by the President of Ukraine, Volodymyr Zelensky, as the primary platform for charitable donations to reconstruct Ukraine.

Nanotech strategy shows promise for treating autoimmune disease

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases.

The scientists, who reported their results on November 23, 2022, in the journal ACS Nano, engineered cell-like "nanoparticles" that target only the immune cells driving an autoimmune reaction, leaving the rest of the immune system intact and healthy.

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies

8 - 9 February 2023, London, United Kingdom.
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

Remdesivir reduces COVID-19 mortality in a real-world setting

The COVID-19 pandemic has led to an explosion of clinical research resulting in the development of a variety of vaccines and treatments, although the efficacy of some remains controversial. Now, researchers from Japan report that remdesivir, a drug whose effectiveness has been debated, appears to make a big difference in Japanese patients with COVID-19 who received corticosteroids in the ICU.

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today, say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses - from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future.

PharmaNews.eu

Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros

Nanotech strategy shows promise for treating autoimmune disease

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies

Remdesivir reduces COVID-19 mortality in a real-world setting

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

More Pharma News ...